Company Overview and News

1
Former Presidential Bodyguard Has a New Job: Protecting Blockchain - Bloomberg

2018-07-19 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
83SF BCS.PR BCS BCS.PRD BCS.PRC 83SK BCS.PRA 47MC

5
Oil's hired hands are looking beyond shale to an overseas "boomlet"

2018-07-19 worldoil
HOUSTON (Bloomberg) -- The world’s biggest oilfield-service companies may have finally found something to talk about beyond the U.S. shale boom.
BHI 83SF BCS.PR BCS.PRD SLB BCS BCS.PRC 83SK BCS.PRA SCL SLB 47MC

1
Remain Cautiously Optimistic On Helmerich & Payne

2018-07-17 seekingalpha
Strong fundamentals and modern rigs with leading market share in US land drilling segment supports the accumulation thesis.
83SF BCS.PR BCS BCS.PRD BCS.PRC 83SK HP BCS.PRA 47MC

10
Lifehacks for when a robot wants your job

2018-07-16 bworldonline
CAN’T CODE, or speak Bahasa? Didn’t go to school with a CEO’s son or daughter? A robot will take your trading seat. Read on if you want to save your job.
NMR BCS.PRD BCS BCS.PRC DB BCS.PRA GS.PRB GS.PRA SFTBF 83SF GS GLSSP D05 83SK 8604 UBS DBSDF NRSCF UBS.PRDCL RWA SFTBY 47MC JBK DBSDY GSC GS.PRICL TFG GSJ GS.PRJ GS.PRI BCS.PR N33 GS.PRD GS.PRC 9984 GJS GS.PRN ULSGF GS.PRK

1
China braces for more pain from trade war

2018-07-14 thestar.com.my
BEIJING: Further evidence of Donald Trump’s trade war with China is set to show up in economic data, although it will likely just be a taste of things to come.
83SF BCS.PR BCS BCS.PRD BCS.PRC 83SK BCS.PRA 47MC

1
China Plays for Time in Trade War With Subtle Shift in Rhetoric - Bloomberg

2018-07-12 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
83SF BCS.PR BCS BCS.PRD BCS.PRC 83SK BCS.PRA 47MC

1
China Braces for More Pain From the Trade War as Economy Slows - Bloomberg

2018-07-12 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
83SF BCS.PR BCS BCS.PRD BCS.PRC 83SK BCS.PRA 47MC

1
Meet the Traders Caught up in Euribor Trial - Bloomberg

2018-07-12 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
CRZBY BCS.PRD BCS BCS.PRC DB BCS.PRA SCGLY 83SF BCS.PR SCGLF 83SK CRZBF GLE 47MC

1
China braces for more pain from the trade war as economy slows

2018-07-12 theedgemarkets
BEIJING (July 12): Further evidence of Donald Trump’s trade war with China is set to show up in economic data due over the next few days, although it will likely just be a taste of things to come.
83SF BCS.PR BCS BCS.PRD BCS.PRC 83SK BCS.PRA 47MC

48
MYND / MYnd Analytics, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-11 fintel.io
MYnd Analytics, Inc. (NASDAQ:MYND) has 8 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 40,333 shares. Largest shareholders include Cannell Peter B & Co Inc, First Foundation Advisors, Hartford Financial Management Inc., UBS Group AG, Bank Of America Corp /de/, First Command Bank, Barclays Plc, and Cwm, Llc.
BCS.PRD BAC BCS BCS.PRC BCS.PRA MYNDW MYAN MYND BAC 83SF BCS.PR 83SK UBS UBS.PRDCL ULSGF 47MC

1
WeWork Rival Convene Raises $152 Million to Fuel Its Expansion - Bloomberg

2018-07-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
BCS.PRD BCS BCS.PRC BCS.PRA BPY CCV CMCSA CCZ 83SF BCS.PR BLK 83SK CCV.CL CMCSK 47MC

11
BlueMountain hires four portfolio managers to build out relative-value focus | Reuters

2018-07-10 reuters
NEW YORK (Reuters) - BlueMountain Capital Management on Tuesday said it hired four portfolio managers to build out the hedge fund’s new fixed-income strategy focused on relative-value investments in G7 government bonds, U.S. municipal bonds, agency ABS and emerging market debt.
BCS.PRD BCS BCS.PRC C.WSA BCS.PRA GS.PRB GS.PRA 83SF GS C.WS.B GLSSP 83SK C.WS.A C.PRP C.PRU 47MC C.PRS JBK C C.PRL GSC GS.PRICL C.PRJ TFG C.PRK C.PRG GSJ C.PRC GS.PRJ GS.PRI BCS.PR C.PRPCL GS.PRD CGBBW GS.PRC GJS GS.PRN GS.PRK

1
Football's coming home, to UK retailers' delight

2018-07-10 sports.yahoo
Shaftesbury (United Kingdom) (AFP) - Mike Angell is on a 300-mile (480-kilometre) round trip in his company van, racing to deliver outsized quantities of booze to social clubs and restaurants in time for England's date with World Cup destiny.
83SF BCS.PR BCS.PRD BCS BCS.PRC 83SK BCS.PRA NG NGGTF NGG 47MC

1
Bank Negara governor has reason to turn more dovish

2018-07-10 thestar.com.my
KUALA LUMPUR: Malaysia’s new central bank governor presides over her first interest-rate meeting in a better position than most of her peers in Southeast Asia.
83SF BCS.PR BCS BCS.PRD BCS.PRC PBLOF 83SK BCS.PRA 1295 47MC

1
Malaysia's New Central Bank Chief Has Reason to Turn More Dovish - Bloomberg

2018-07-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
83SF BCS.PR BCS BCS.PRD BCS.PRC PBLOF 83SK BCS.PRA 1295 47MC

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 003134865